Clinical Trials · NCT01212133
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,386
- Start date
- Nov 2010
- Locations
- 1 site, India
- Primary endpoint
- The number of serious adverse drug reactions (SADRs) during the study period